Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Motivation explains disconnect between testing, real-life functioning for seniors

  • Novel technologies advance brain surgery to benefit patients

  • Mutated gene linked to both autism, intellectual disability

  • New concerns over top-selling blood thinning drug after investigation

  • Immune response may cause harm in brain injuries, disorders

  • New mechanism for neurodegeneration found

  • New tools help neuroscientists analyze 'big data'

  • Six new genetic risk factors for Parkinson's found

  • CEOs who motivate with 'fightin' words' shoot themselves in the foot

  • Knowledgeable consumers more likely to buy when given fewer options

  •